remote patient's management
Behavioralscheduled remote CareLink data transmission
Other names: home monitoring
NCT Number: NCT01216670
The CARRYING ON for heart failure (HF) study is a national, prospective, post market interventional, multi-center, open-label, pilot trial.The purpose of the study is to assess a short term and a long term period, incidence of pre-specified clinical and arrhythmic events in patients with a low ejection fraction (EF) that are hospitalized for acute cardiac decompensation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria, Italy
The CARRYING ON for heart failure (HF) study is a national, prospective, post market interventional, multi-center, open-label, pilot trial designed in two phases.
The purpose of the study is to assess a short term (6 months follow-up - Phase 1) and a long term period (24 months follow-up - Phase 2), incidence of pre-specified clinical and arrhythmic events in patients with a low ejection fraction (EF) that are hospitalized for acute cardiac decompensation. A previously implanted Reveal® XT device will be used to collect heart rhythm information.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
scheduled remote CareLink data transmission
Other names: home monitoring
Time frame: implant to 6 months post-implant
In patients with low ejection fraction that are hospitalized for acute cardiac decompensation, the pre-specified events include:
Time frame: implant to 24 months post-implant
In patients with low ejection fraction that are hospitalized for acute cardiac decompensation, the pre-specified events include:
Time frame: implant to 6 months post-implant
Document the incidence of the pre-specified secondary clinical and arrhythmic events in patients implanted with the Reveal XT.
The pre-specified secondary clinical and arrhythmic events are:
Time frame: implant to 24 months post-implant
Document the incidence of the pre-specified secondary clinical and arrhythmic events in patients implanted with the Reveal XT.
The pre-specified secondary clinical and arrhythmic events are:
Medtronic Italia
Industry
Acronym: CARRYINGON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03446651
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05806606
Behavior, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT06847438
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07721909
Cardiovascular Diseases, Heart Diseases
Muscat, Oman
View Trial Details